 JUPITER, FL ACCESSWIRE May 24, 2021 Dyadic International, Inc. Dyadic, or the Company NASDAQ:DYAI a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that the Company will participate in the following upcoming events: Jefferies Virtual Healthcare Conference Tuesday, June 1, 2021 at 9:00 a.m. ET. Mark Emalfarb, President and CEO of Dyadic, will provide a corporate overview and update on the Companys progress in advancing its C1-Cell Protein Production Platform for use in reducing the costs of manufacturing proteins for animal and human health applications, mostly notably its COVID-19 vaccine candidate, DYAI-100, toward a first-in-human Phase 1 clinical trial later this year. 